乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

TCT

<乌鸦传媒>Aortic Regurgitation Device Passes in Pivotal Trial

JenaValve device hits benchmarks with improvement in pacemaker rates

<乌鸦传媒>Combining TAVR, LAA Closure in Same Procedure Safe, Trial Says

WATCH-TAVR suggests percutaneous approach can follow surgical pattern in not staging procedures

<乌鸦传媒>Amulet vs Watchman Comparison Still Muddy Any Which Way LAA Leaks Are Defined

The two devices continue to lead to similar clinical outcomes

<乌鸦传媒>Low-Risk TAVR Converging or Diverging With Surgical Outcomes, Depending on the Valve

Intermediate-term reports from PARTNER 3 and Evolut Low Risk trials

<乌鸦传媒>PCSK9 Inhibitor Passes Muster for LDL Reduction in Acute Coronary Syndrome

Question now is whether routine early treatment will translate to better clinical outcomes

<乌鸦传媒>Brief Anticoagulation Preserves Radial Artery After Catheter Access

Trial shows promise of a short course of direct-acting oral anticoagulant

<乌鸦传媒>PCI vs CABG: Does Age Inform Choice for Left Main Coronary Artery Disease?

Swedish registry study contributes to ongoing controversy

<乌鸦传媒>Pulmonary Artery Denervation Improves PAH Symptoms

Trial promising for novel technique

<乌鸦传媒>RDN Powers Through Another Off-Med Trial, Clinical Benefits Still Untested

Plus, an apparent magnification of effect in SYMPLICITY HTN-3

<乌鸦传媒>PCI Not (Much) Worse Than CABG for Multivessel Disease Long Term

Extended follow-up of BEST trial appeared unlikely to change minds, though

<乌鸦传媒>Ultrasound Guidance No Advantage for PCI Access

But randomized trial still suggests some reasons to consider this readily available intervention

<乌鸦传媒>MitraClip G4 Sets the Bar Higher for Transcatheter Edge-to-Edge Repair

Post-approval study suggests growing pool of TEER-suitable patients

<乌鸦传媒>Clot Grabber Safe, Promising in Intermediate-Risk PE

Registry supports expanding use of interventional treatment

<乌鸦传媒>Post-MI Ventricular Septal Defect Repair Strategies: Each Has Its Place for Now

Registry study compares percutaneous vs surgical outcomes in real-world practice

<乌鸦传媒>Is TAVR in Small Aortic Annuli Better With Self-Expanding Valves?

Registry supports mortality impact of patient-prosthesis mismatch

<乌鸦传媒>Mitral Valve Repair Devices Go Head-to-Head, and the Top Spot Belongs to...

CLASP IID trial crowns no winner but champions expanding choices

<乌鸦传媒>Presumed Clinical Benefits of TAVR Cerebral Protection Remain Unproven

Large trial comes up short in proving a definitive benefit to debris filters

<乌鸦传媒>DCBs for the Coronaries: Early Victories for New Drug Coatings

Researchers eye next gen drug-coated balloons despite lack of FDA OK for use in PCI

<乌鸦传媒>Gastrointestinal Damage Nearly Universal With Antiplatelet Use After PCI

Noninvasive endoscopy in OPT-PEACE reveals surprises about GI effects of antiplatelets

<乌鸦传媒>Pulmonary Pressure Monitoring Helps HFpEF Too

GUIDE-HF substudy supports similar benefits across the ejection fraction spectrum

<乌鸦传媒>Is LAA Closure With Amulet Less Leaky?

Two studies, IDE and SWISS-APERO, come to disparate conclusions

<乌鸦传媒>Short DAPT Just as Good for High-Bleeding Risk Stenting After MI

MASTER-DAPT is "good news" on a the key clinical concern

<乌鸦传媒>Longstanding Vascular Closure Technique Triumphs Over Collagen Plug

Manta versus ProGlide after transfemoral TAVR in CHOICE-CLOSURE

<乌鸦传媒>TAVR Chugging Along at 5 Years in SURTAVI Trial

Plus, data suggest that it is probably cost-effective in low-risk patients

<乌鸦传媒>LAA Closure Holds Up Against NOACs

Longer-term follow-up from the PRAGUE-17 trial reassures

<乌鸦传媒>TAVR Operators Divided on Need for Bicuspid RCT

Odds of a study coming to fruition are low

<乌鸦传媒>Adenosine-Free Alternative to FFR Bolstered by Longer-Term Data

Physiological index boasts good 5-year results in iFR-SWEDEHEART

<乌鸦传媒>No-Pressure-Wire Physiology Boosts PCI Outcomes

Chinese trial shows advantage over visual assessment alone

<乌鸦传媒>Surgery Keeps Edge Over Contemporary Stenting for Multivessel CAD

Large noninferiority margin still not enough in FAME 3 trial

<乌鸦传媒>Novel Stent Gets 'Sweet' Victory in Diabetes Patients

SUGAR trial shows superiority of polymer-free stent eluting fatty acid-bound sirolimus

<乌鸦传媒>No Aspirin Post-STEMI Stent; Sapien 3 Stroke Risk; and More

It's a TICO-STEMI, SOLVE-TAVI, FLASH, and IREMMI trial data round-up

<乌鸦传媒>'Drug-Based Therapy is Here to Stay' in Angioplasty for PAD

TCT Connect studies report reassuring safety data, promise in challenging segments

<乌鸦传媒>TAVR For Failing TAVR Doesn't Impress in Registry Data

5 year data for TAVR after SAVR looks "more optimistic"

<乌鸦传媒>Sobering Efficacy Data for TriGuard 3 Deflector in TAVR

Randomized trials on embolic protection devices are ongoing

<乌鸦传媒>COVID Heart Autopsies Point More to Clot Damage Than Myocarditis

Results bolster case for anticoagulation in hospitalized patients

<乌鸦传媒>ACS Patients Benefit From Bivalirudin During PCI, Pooled Data Show

Risks can be mitigated with infusion strategy, patient-level meta-analysis finds

<乌鸦传媒>Registry: Door-to-Balloon Times No Slower in COVID-19 Patients

North American registry shows worse outcomes even so

<乌鸦传媒>Is PCI the Answer to Vulnerable Plaques That Don't Limit Flow?

Some success with BVS placement in PROSPECT ABSORB

<乌鸦传媒>OCT Vs FFR: Which Is the Better Guide for Revascularization?

Optical coherence tomography goes up against physiological guidance in angiographically intermediate coronary lesions

<乌鸦传媒>TAVR at 5 Years: Paravalvular Regurgitation is Key

"No matter what you're using, you have to decrease PVR"

1